NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

28 May 2014

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has received a negative opinion from UK watchdog the National Institute for Health and Care Excellence (NICE) which, in a final guidance published today, does not recommend National Health Service use of the firm’s Stelara (ustekinumab) for the treatment of psoriatic arthritis.

The NICE Independent Appraisal Committee examined the clinical and cost effectiveness of using ustekinumab alone or in combination with methotrexate, for treating active psoriatic arthritis in adults when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. This final guidance does not mean that people currently taking ustekinumab will stop receiving it. They have the option to continue treatment until they and their clinicians consider it appropriate to stop.

Not a cost-effective option

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK